About Ceftriaxone and Tazobactam Injection — Composition & Mechanism
Ceftriaxone and Tazobactam Injection is a fixed-dose sterile combination of two complementary antibacterial agents — formulated specifically for intravenous and intramuscular administration in hospital and critical care settings.
Ceftriaxone Sodium 1000mg is a broad-spectrum, third-generation cephalosporin that disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial lysis and death. Its long half-life allows once or twice-daily dosing and its penetration across the blood-brain barrier makes it particularly effective in central nervous system infections.
Tazobactam Sodium 125mg is a beta-lactamase inhibitor — it does not kill bacteria on its own but plays a critical defensive role by irreversibly blocking the beta-lactamase enzymes that many resistant bacteria produce to neutralise cephalosporins. This protection significantly expands the spectrum of activity of ceftriaxone against beta-lactamase-producing organisms that would otherwise be resistant.
Together, this combination delivers dual-action antibacterial efficacy against a wide range of gram-positive, gram-negative, and beta-lactamase-producing pathogens — making it one of the most clinically relevant inj ceftriaxone tazobactam formulations in modern hospital antibiotic therapy and a high-demand product for third party pharmaceutical manufacturing in India.
Ceftriaxone and Tazobactam Injection Uses — Indications & Therapeutic Applications
Understanding the full scope of ceftriaxone and tazobactam injection uses is essential for healthcare professionals, hospital procurement teams, and pharma distributors evaluating this product for formulary inclusion or third party manufacturing partnerships.
Pneumonia & Lower Respiratory Tract Infections
One of the primary ceftriaxone and tazobactam injection uses is in community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The combination is highly effective against the common bacterial pathogens responsible for severe respiratory infections, including beta-lactamase-producing organisms that resist standard cephalosporins.
Urinary Tract Infections (UTIs)
Severe and complicated UTIs — including pyelonephritis and catheter-associated infections — respond well to injection ceftriaxone tazobactam, particularly where resistant gram-negative pathogens like E. coli are involved. It is a preferred antibiotic injection for UTI treatment in hospitalised patients.
Bacterial Septicemia & Sepsis
As an IV antibiotic for critically ill patients, inj ceftriaxone and tazobactam is indicated in bacteremia and sepsis where broad-spectrum empirical coverage is required pending culture sensitivity results — particularly in ICU and emergency medicine settings.
Bacterial Meningitis
Ceftriaxone's ability to cross the blood-brain barrier makes this combination a clinically important meningitis antibiotic injection treatment option, effective against common CNS pathogens including Neisseria meningitidis and Streptococcus pneumoniae.
Intra-Abdominal Infections
Peritonitis, cholangitis, and other intra-abdominal bacterial infections caused by mixed gram-positive/gram-negative flora are effectively managed with ceftriaxone & tazobactam for injection, particularly in post-surgical and intensive care patients.
Skin, Soft Tissue & Wound Infections
Complex skin and soft tissue infections, including surgical site infections and infected wounds with suspected resistant bacterial involvement, are a recognised indication for this combination antibiotic injection.
Bone & Joint Infections
Osteomyelitis and septic arthritis requiring IV antibiotic therapy in hospital settings represent an important application of ceftriaxone and tazobactam for injection, especially in patients requiring prolonged parenteral antibiotic courses.
Surgical Prophylaxis
Pre-operative single-dose IV administration is used for peri-operative prophylaxis against surgical site infection — a key hospital-segment use for broad spectrum antibiotic injection in elective and emergency surgical procedures.
Antibiotic-Resistant Infections As antibiotic resistant infection treatment in India becomes an increasing clinical priority, the tazobactam component directly addresses beta-lactamase-mediated resistance — making this combination a critical tool in antimicrobial stewardship programmes.
Sterile Injectable Manufacturing Facility — cGMP Certified, ISO Compliant
Delwis Healthcare's sterile injectable manufacturing infrastructure is purpose-built for producing ceftriaxone and tazobactam injection and similar high-sensitivity antibiotic formulations with zero compromise on sterility, potency, or regulatory compliance.
Our GMP certified injectable manufacturing facility in Gujarat operates under strictly controlled aseptic conditions, with key capabilities including:
- ISO Class 7 Cleanrooms — Controlled environment aseptic processing zones for all sterile filling operations
- Aseptic Filling Lines — Validated filling systems for dry powder injectables and WFI-reconstitutable vial presentations
- Advanced Filtration Systems — Multi-stage filtration for bioburden control and endotoxin reduction
- Lyophilisation Capability — Supporting moisture-sensitive API formulations requiring freeze-dried presentation
- In-line pH, Osmolarity & Particulate Matter Monitoring — Real-time critical quality parameter surveillance during production
- Full Batch Traceability — Electronic batch records and validated documentation systems for regulatory audit readiness
- Scalable Production Capacity — From development batches to large-volume commercial supply with consistent quality output
Third Party Manufacturing & Contract Manufacturing — Ceftriaxone Tazobactam Injection
Delwis Healthcare is a trusted third party pharmaceutical manufacturer and CDMO partner for ceftriaxone tazobactam injection — offering complete outsourced manufacturing services to pharma brands, hospital supply companies, and export distributors across India and international markets.
Our Injectable Manufacturing Services
Third Party Manufacturing Manufacture inj ceftriaxone tazobactam under your registered brand with full GMP-compliant production, quality testing, and labeling support — with no capital investment required from your side.
Contract Manufacturing (CDMO)
End-to-end manufacturing partnership covering API sourcing, sterile formulation development, scale-up, validation, commercial batch production, stability studies, and supply chain management for your ceftriaxone and tazobactam injection requirements.
Private Label Manufacturing
Launch your own branded sterile antibiotic injection with custom artwork, carton design, vial labeling, and packaging specifications for target domestic or export markets.
DPCO-Compliant Supply
Our DPCO injection manufacturer capability ensures the product is manufactured and supplied in full compliance with Drug Price Control Order regulations — essential for government tenders, institutional supply, and hospital formulary procurement.
Export-Ready Manufacturing
Full regulatory documentation support including stability data, COA, COPP, and FSC for pharmaceutical exporters targeting markets in Africa, Southeast Asia, and the Middle East.
Whether you are building a hospital antibiotic portfolio, expanding into critical care injectables, or sourcing a cephalosporin injection contract manufacturing partner in Gujarat — Delwis Healthcare delivers production-ready solutions with regulatory confidence.
Packaging & Storage — Ceftriaxone Tazobactam 1125mg Injection
Ceftriaxone and Tazobactam Injection is supplied as a sterile dry powder for reconstitution, packaged in:
- 1 Glass Vial (10ml, bromobutyl rubber stopper with flip-off aluminium seal)
- 1 Ampoule of Water for Injection (WFI) — supplied as diluent
- Unit carton with pack insert for retail and institutional distribution
Storage Instructions:Store below 30°C. Protect from direct light and moisture. Keep out of reach of children. Once reconstituted, the solution should be used immediately as per prescribing guidelines.
Custom packaging configurations for bulk supply, government tender, and export markets can be accommodated on request.
Quality Control — WHO-GMP Antibiotic Injection Manufacturer India
Every batch of ceftriaxone and tazobactam injection manufactured at Delwis Healthcare undergoes a rigorous, multi-layered quality control process aligned with international pharmacopoeial standards:
- HPLC Analysis — Quantitative determination of ceftriaxone sodium and tazobactam sodium per batch
- Sterility Testing — Full sterility confirmation per USP/BP/EP requirements
- Bacterial Endotoxin Testing (BET) — LAL-based pyrogen testing for injectable safety assurance
- Particulate Matter Inspection — Both automated and visual inspection for sub-visible and visible particles
- Reconstitution Testing — Clarity, colour, pH, and osmolarity verification post-reconstitution
- Stability Studies — Real-time and accelerated stability data available to support regulatory dossier submissions
- In-Process Quality Monitoring — Continuous surveillance of critical parameters throughout the production cycle
Why Choose Delwis Healthcare as Your Ceftriaxone Tazobactam Injection Manufacturer
Pharma brands, hospital supply companies, and export distributors choose Delwis Healthcare for ceftriaxone and tazobactam injection manufacturing because of:
- WHO-GMP & ISO 9001/14001 Certification — Globally accepted manufacturing compliance credentials
- Dedicated Sterile Injectable Facility — Purpose-built aseptic infrastructure with ISO Class 7 cleanrooms
- DPCO Expertise — Manufacturing experience with Drug Price Control Order products for Indian institutional markets
- Full CDMO Support — From formulation to regulatory documentation to commercial supply
- Flexible MOQ — Scalable from pilot validation batches to large-volume commercial orders
- Export Documentation Ready — COA, COPP, FSC, and stability data available for global market registrations
- Competitive Pricing — Cost-efficient sterile manufacturing from Gujarat, India without quality trade-offs
- Dedicated Account Management — Responsive commercial and technical support for every client partner
Frequently Asked Questions — Ceftriaxone and Tazobactam Injection
Q1: What is ceftriaxone and tazobactam injection used for?
Ceftriaxone and tazobactam injection uses span a wide range of serious bacterial infections managed in hospital settings. These include pneumonia, urinary tract infections, bacterial septicemia, meningitis, intra-abdominal infections, skin and soft tissue infections, bone and joint infections, and peri-operative surgical prophylaxis. The tazobactam component specifically extends efficacy against beta-lactamase-producing drug-resistant organisms, making it a critical choice for antibiotic resistant infection treatment in India.
Q2: How does ceftriaxone and tazobactam work?
Ceftriaxone — a third generation cephalosporin injection — works by inhibiting bacterial cell wall synthesis, causing bacterial cell death. Tazobactam acts as a beta-lactamase inhibitor, blocking the enzymes that resistant bacteria produce to destroy cephalosporins. Together, they deliver broader and more durable antibacterial action than ceftriaxone alone — particularly against gram-negative, gram-positive, and beta-lactamase-producing pathogens.
Q3: What is the difference between ceftriaxone and ceftriaxone tazobactam injection?
Plain ceftriaxone injection is effective against bacteria that are inherently susceptible to cephalosporins. Ceftriaxone and tazobactam for injection adds tazobactam, which protects ceftriaxone from enzymatic degradation by resistant bacteria. This makes the combination significantly more effective against beta-lactamase-producing strains — expanding the spectrum of coverage in clinically complex or resistant infections.
Q4: Can ceftriaxone tazobactam injection be used in children?
Yes, with appropriate dose adjustment under medical supervision. Paediatric dosing is typically calculated on a per-kg basis (generally 50–75 mg/kg/day in terms of ceftriaxone) in divided doses, not exceeding 2g/day total. Clinical judgment and culture sensitivity results should guide the treating physician's decision for paediatric use.
Q5: What are the side effects of ceftriaxone tazobactam injection?
Side effects are generally mild to moderate and may include injection site reactions (pain, redness), nausea, diarrhoea, elevated liver enzymes, and hypersensitivity reactions such as rash or itching. Less commonly, haematological changes including eosinophilia or thrombocytopenia may occur. Patients with cephalosporin or penicillin hypersensitivity should be assessed carefully before administration. Always use under qualified medical supervision.
Q6: Do you offer third party manufacturing for ceftriaxone tazobactam injection?
Yes. Delwis Healthcare is a WHO-GMP certified sterile injectable contract manufacturing partner offering full third party manufacturing of ceftriaxone and tazobactam injection (1000mg + 125mg, DPCO) under client brand names — including private labeling, custom packaging, and complete regulatory documentation for Indian and export markets.
Q7: What certifications does your injectable manufacturing facility hold?
Our facility holds WHO-GMP, ISO 9001, and ISO 14001 certifications. All injectable manufacturing follows USP, BP, and EP pharmacopoeial standards, with full batch documentation and regulatory compliance records maintained for domestic and export market submissions.
Q8: What is the storage condition for ceftriaxone tazobactam injection?
The injection should be stored below 30°C, away from direct sunlight and moisture. The sealed vial maintains integrity under these conditions until the labelled expiry date. Post-reconstitution, the solution should be administered promptly as per the prescriber's instructions and not stored for reuse.
Q9: What is the minimum order quantity for contract manufacturing?
MOQ is flexible and tailored to batch size, packaging requirements, and market specifications. Contact our team at info@delwishealthcare.com for a detailed quote based on your requirements.
Q10: Is this injection DPCO compliant?
Yes. Ceftriaxone and Tazobactam Injection (1000mg + 125mg) is listed under the Drug Price Control Order (DPCO) and our manufacturing process is fully aligned with DPCO compliance requirements — making it suitable for government institutional procurement, hospital formularies, and regulated market supply in India.
